Project Grant R01AI179974
Award Date
7/11/24
Completion Date
5/31/29
Dollars Obligated
$3.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a Project Grant (CFDA 93.859 Biomedical Research and Research Training) to Mayo Clinic Arizona, a nonprofit academic medical center, totaling $1,248,750.00 from August 1, 2024 to May 31, 2029. The grant supports research to develop durable cell-based therapies for treating chronic diseases such as hemophilia, diabetes, and liver disorders. The project aims to engineer cells that can be transplanted and function long-term within...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $817,161 to investigate the use of mesenchymal stem cells (MSCs) derived from the human gut as a novel autologous cell therapy for treating perianal fistulas, a serious complication of Crohn's disease. The 3-year research project, led by Mercer University in Macon, Georgia, aims to characterize the potency and...
This $306,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports preclinical studies to evaluate the efficacy of Mink Therapeutics' cellular immunotherapy product, Agent-797, in reducing graft-versus-host disease (GVHD) and improving immune engraftment following hematopoietic stem cell transplantation (HSCT). The project, conducted in collaboration with researchers at the...
This $306,872 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research) aims to develop an allogeneic cell-based gene therapy product for the treatment of mucopolysaccharidosis type IVA (MPS IVA), a rare genetic disorder. The key objectives are to produce, optimize, and analyze genetically-modified cells in vitro to systemically deliver supraphysiologic levels of the enzyme...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $612,975.00 to the University of Pittsburgh to conduct research aimed at achieving long-term organ transplant acceptance without the need for maintenance immunosuppression. The key goals are to develop a translational model that combines T-cell costimulation blockade with inhibition of monocyte allorecognition via...
This Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development of novel cellular therapies for the treatment of glioblastoma (GBM), a highly aggressive form of brain cancer. The $417,858 award, effective from January 7, 2025 through December 31, 2029, will enable researchers at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to engineer mesenchymal stem cells (MSCs) to release...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $104,435 to support Dr. Sonali Bracken's research at Duke University. The objective is to delineate immune pathways that contribute to lung fibrosis in patients with chronic graft-versus-host disease (CGVHD). The research aims to examine how B cells and fibroblasts undergo crosstalk that promotes lung fibrosis,...
This Project Grant award, valued at $1,821,515.00 and effective July 22, 2024 through May 31, 2029, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this research is to develop and evaluate bi-specific chimeric antigen receptors (CARs) that can recognize both cytomegalovirus (CMV) and HIV-1 antigens. This approach aims to create cytotoxic T lymphocytes (CTLs) that can be...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute (NHLBI) under CFDA Program 93.837 "Cardiovascular Diseases Research," supports a comprehensive research program to investigate the role of mucus-degrading intestinal bacteria in complications related to hematopoietic cell transplantation (HCT). The total funding amount is $2,594,544, with an award date of September 21, 2024 and an ultimate completion date of July 31, 2029. The program consists...
This $1,648,086 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the use of CD20-targeted CAR T cell therapy to deplete B cells and induce immune tolerance in kidney transplant recipients. The research aims to promote long-term kidney allograft survival in non-human primates by modifying the B and T cell repertoires. Key research activities include...